Celcuity is a healthcare company focused on developing innovative cancer therapies. Its core product is the Celcuity platform, which utilizes a proprietary technology to identify and target specific cancer cell types. The company primarily operates in the oncology segment, generating revenue through partnerships and collaborations with pharmaceutical companies for drug development and clinical trials.
The investment profile of Celcuity is more aligned with growth investors, given its focus on developing new therapies and potential market expansion. The company does not currently offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, with moderate liquidity reflecting the stock's trading characteristics.
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-03 02:36 | Mantener | Vender | scenario_deterioration |
| 2026-05-08 15:34 | — | Mantener | Weak fundamentals with high volatility and uncertain market signals. |
| 2026-05-05 02:37 | — | Mantener | Компания демонстрирует значительный рост цен за последние месяцы, что указывает на позитивные ожидания рынка. Однако отрицательный EPS и высокая волатильность требуют осторожности. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-06-03 12:48 | Craig-Hallum | Objetivo reducido | 189 → 171 | 89.1199 |
| 2026-06-03 10:07 | H.C. Wainwright | Objetivo reducido | 185 → 145 | 91.42 |
| 2026-06-03 09:28 | Wells Fargo | Objetivo reducido | — → 166 | 91.42 |
